◭ V-Series Protocol
Triple-receptor weight reduction with sustained energy
Every component is individually sourced and third-party verified. Tap any compound for its full clinical reference.
An advanced weight-loss stack built around Retatrutide, a newer triple-action compound, for people who have plateaued on other options. Includes BPC-157 for digestive comfort during the build-up phase.
CLINICAL INDICATION: Refractory metabolic dysfunction, dual-agonist plateau, advanced weight reduction research
Advanced metabolic protocol anchored by Retatrutide's simultaneous activation of GLP-1, GIP, and glucagon receptors. The glucagon pathway adds energy-expenditure and hepatic-lipid-mobilization effects absent in dual-agonist regimens. Tesamorelin preserves lean mass and dermal collagen during aggressive fat reduction. BPC-157 can be added - commonly paired with V-M2 given Retatrutide's higher GI side-effect profile relative to tirzepatide.
Dual-agonist therapy (GLP-1/GIP) addresses appetite and insulin sensitivity but does not directly increase energy expenditure. Retatrutide's glucagon-receptor activity adds a thermogenic and hepatic-lipid-clearance mechanism that produced higher cohort weight reduction than Tirzepatide in early-phase trials. V-M2 pairs this with structural-preservation support so that aggressive reduction does not come at the cost of lean mass or dermal architecture. The GI side-effect burden is meaningful - BPC-157 is commonly paired with V-M2 given the higher tolerability stress relative to tirzepatide. Retatrutide is investigational - not a first-line option.
| What's in the box | Specification | Per month |
|---|---|---|
| Retatrutide | 10mg vial · once-weekly administration covers ~4 weeks | 1× |
| Tesamorelin | 10mg vial · typical monthly allocation | 1× |
| BPC-157 | 5mg vial · 2 vials typical monthly supply for adjunct support | 2× |
GLP-1 class - Tirzepatide, Retatrutide, Semaglutide, Cagrilintide, V-03, V-M2
These protocols work on appetite, insulin sensitivity, and how your body stores fat. Monitoring tracks both the metabolic benefit and the things that change quickly during weight loss - blood sugar, lipids, and lean-mass markers.
Incremental approach. Doses are titrated upward slowly from a low starting point. Maintenance is typically a moderate dose - pushing higher rarely adds benefit and adds side effects. Monitoring guides where you settle.
Educational only - not medical advice or a dosing instruction. Your own doctor orders tests, interprets results and decides what is right for you. See the Informed Consent & Disclaimer for full terms.
Rapid GLP-1/GIP weight loss reduces fat and lean muscle. The foundation for preserving muscle is resistance training and adequate protein (roughly 1.2–1.6 g/kg/day for most people losing weight) - these do most of the work and come first.
As an adjunct, some people consider a GH-axis secretagogue stack, on the rationale that supporting the growth-hormone / IGF-1 axis may help protect lean mass during a caloric deficit. This is mechanistically reasonable but not established by combination-outcome trials - there is no study showing it preserves more muscle than training and protein alone. Whether it is appropriate is a question for your own doctor.
Educational only - not a recommendation to combine compounds or a dosing instruction.
| Biomarker | Why It's Monitored | Baseline | Cadence |
|---|---|---|---|
| HbA1c | Glycemic control; glucagon-receptor activity can shift glucose handling | Yes | Wk 8, 16, 24 |
| Fasting insulin | Insulin sensitivity trend; core efficacy signal for metabolic recomposition | Yes | Wk 8, 16, 24 |
| Fasting glucose | Hypo/hyperglycemia surveillance through titration | Yes | Each checkpoint |
| Lipid panel (fractionated) | Glucagon pathway mobilizes hepatic lipids; track LDL-P, ApoB, triglycerides | Yes | Wk 8, 16, 24 |
| ALT / AST | Hepatic safety; hepatic-lipid mobilization warrants liver-enzyme surveillance | Yes | Wk 8, 16, 24 |
| Hepatic panel (full) | Broader liver-function picture if ALT/AST trend upward | Yes | As clinically indicated |
| IGF-1 | Tracked when paired with Tesamorelin; growth-axis surveillance | Yes | Wk 8, 16, 24 |
| Lean mass (DEXA) | Aggressive fat reduction risks lean-mass loss; confirm preservation | Yes | Wk 8, 16, 24 |
| Resting heart rate / BP | GLP-1-class agents can affect heart rate; baseline cardiovascular check | Yes | Each checkpoint |
| Renal panel (eGFR, creatinine) | Volume status and renal safety during GI-driven intake changes | Yes | Wk 8, 16, 24 |
| Amylase / lipase | Pancreatic-safety surveillance (class-wide caution) | Yes | If symptomatic / indicated |
| Thyroid (TSH) + MTC screen | Class contraindication screen (MTC/MEN2) before and during | Yes | Baseline; re-screen if indicated |
| Body weight / waist | Primary efficacy outcome; rate-of-loss informs titration pace | Yes | Each checkpoint |
| GI tolerability log | Nausea/satiety/transit guide titration speed and supportive care | Yes | Ongoing, every checkpoint |
Phase 2 randomized controlled trial in 338 adults with obesity. At the 12 mg dose, mean weight reduction was approximately 24.2% over 48 weeks versus ~2% in the placebo group. Gastrointestinal adverse events were dose-related, predominantly mild-to-moderate. The study established proof-of-concept for triple GLP-1/GIP/glucagon receptor activation; Retatrutide remains investigational and not an approved therapy.
View on publisher ↗Phase 2 trial in 281 adults with type 2 diabetes. At the 12 mg dose, mean body-weight reduction was approximately 16.9% at 24 weeks, with clinically meaningful improvements in HbA1c. Magnitude of weight reduction was notable given that weight loss in type 2 diabetes has historically been harder to achieve than in obesity alone. Results supported progression to the Phase 3 TRIUMPH programme.
View on publisher ↗Phase 2a sub-study in adults with MASLD. The 12 mg dose produced reductions in liver fat content of approximately 82–86% with a high proportion of participants achieving normalisation of liver fat. Effects were dose-dependent. Findings positioned Retatrutide as a candidate for MASLD/MASH indications, now under further Phase 3 investigation.
View on publisher ↗Pivotal Phase 3 RCT in HIV-associated lipodystrophy over 26 weeks. Tesamorelin produced selective reduction in visceral adipose tissue versus placebo, with improvements in lipid profile and no significant glycaemic worsening at the studied dose. This trial supported the FDA approval for the lipodystrophy indication. Use outside this indication is off-label.
View on publisher ↗PRISMA-compliant systematic review (36 studies, 1993–2025) summarising the BPC-157 evidence base. The authors documented BPC-157's mechanistic profile (growth hormone receptor enhancement, angiogenesis modulation, anti-inflammatory pathways) across preclinical IBD, GI ulcer, NSAID-induced injury, fistula, and anastomotic models. Critically, the review states: "No clinical safety data is available to date" - i.e. despite extensive preclinical activity, controlled human safety and efficacy data remain absent in the modern peer-reviewed literature.
View on publisher ↗Early Croatian Phase I/II clinical trials (PL10, PL14736) explored BPC-157 in mild-to-moderate ulcerative colitis, reporting safety and tolerability signals in small cohorts. Important caveats: these trials were conducted primarily by BPC-157's discoverers and have not been independently replicated in Western peer-reviewed RCTs at scale; detailed trial reports have not appeared in major Western journals despite frequent reference in subsequent reviews. The 2024 Sikiric et al. review summarises three decades of work but is from the originating group. Independent confirmatory trials remain absent.
View on publisher ↗In-vitro study on isolated Achilles tendon fibroblasts. BPC-157 produced time- and dose-dependent upregulation of Growth Hormone Receptor expression at the mRNA and protein level, with increased fibroblast proliferation markers. Mechanistic and preclinical; does not constitute evidence of efficacy in human tissue repair.
View on publisher ↗Preclinical study mapping cellular pathways. Identified BPC-157 activity on the FAK–paxillin migration pathway, with enhanced cell outgrowth and survival in tendon-explant models. Cellular/animal level; human controlled trial evidence remains absent.
View on publisher ↗Comprehensive narrative review of BPC-157 wound-healing data across skin wounds, burns, diabetic ulcers, alkali burns, and a distinctive body of fistula-healing work (colocutaneous, gastrocutaneous, esophagocutaneous, duodenocutaneous, vesicovaginal, rectovaginal). Documents the angiogenic mechanism - BPC-157 upregulates VEGF-a and promotes endothelial proliferation and vascular tube formation, with an angiogenic effect exceeding standard agents in the sponge assay. Two important caveats: (1) the evidence is almost entirely animal (rat/mouse, some pig) - not human outcome data; (2) it is a review by the originating Zagreb group, and most primary citations are that group's own work, so it has not been independently replicated at scale. Note also that the same pro-angiogenic/VEGF action that drives healing is the basis for the theoretical oncologic caution discussed for any angiogenic compound.
View on publisher ↗Review proposing BPC-157 as a candidate for cancer cachexia (cancer-related muscle/fat wasting). In a C-26 colon-adenocarcinoma mouse model the peptide antagonised TNF-α and IL-6, cytokines central to cachexia. Preclinical and pre-clinical-trial - a proposal, not an outcome study - and from the originating (Sikiric) group.
View on publisher ↗In vitro: BPC-157 (2–10 ng) reduced human melanoma cell S-phase fraction by up to ~55% and decreased ERK phosphorylation - i.e. it acted as an antimitogenic agent INHIBITING the VEGF-MAPK proliferative signal in melanoma cells. A conference abstract (no full text), from the originating group; counterintuitive against the “BPC promotes angiogenesis” healing literature, which is why both directions matter.
View on publisher ↗A 2025 review in which the originating group directly addresses the tumour-risk speculation: it argues BPC-157 CONTROLS/MODULATES angiogenesis rather than driving tumorigenesis (e.g. it opposes corneal neovascularisation - “angiogenic privilege”), reports anti-tumour potential in vitro and in vivo per Folkman’s concept, and notes LD1 not achieved with no reported adverse effects. Important read: this is a defence authored by the compound’s originating group, so it answers but does not independently close the theoretical tumour-risk question.
View on publisher ↗Every lot is independently tested and the report is published on this page. International shipping $35, free on orders of $250 or more. Research use only, adults 21 and over.
Are you 21 years of age or older?